Alta Biopharma Partners Iii Lp - Net Worth and Insider Trading

Alta Biopharma Partners Iii Lp Net Worth

The estimated net worth of Alta Biopharma Partners Iii Lp is at least $5 Million dollars as of 2024-11-13. Alta Biopharma Partners Iii Lp is the 10% Owner of Aegerion Pharmaceuticals Inc and owns about 2,336,387 shares of Aegerion Pharmaceuticals Inc (AEGR) stock worth over $5 Million. Alta Biopharma Partners Iii Lp is also the of Molecular Templates Inc and owns about 215 shares of Molecular Templates Inc (MTEM) stock worth over $71. Details can be seen in Alta Biopharma Partners Iii Lp's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Alta Biopharma Partners Iii Lp has not made any transactions after 2012-10-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Alta Biopharma Partners Iii Lp

Alta Biopharma Partners Iii Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Alta Biopharma Partners Iii Lp owns 10 companies in total, including Cara Therapeutics Inc (CARA) , Macrogenics Inc (MGNX) , and CymaBay Therapeutics Inc (CBAY) among others .

Click here to see the complete history of Alta Biopharma Partners Iii Lp’s form 4 insider trades.

Insider Ownership Summary of Alta Biopharma Partners Iii Lp

Ticker	Comapny	Transaction Date	Type of Owner
CARA	Cara Therapeutics Inc	2014-01-30	10 percent owner
MGNX	Macrogenics Inc	2013-10-09	10 percent owner
CBAY	CymaBay Therapeutics Inc	2013-10-11	10 percent owner
		2013-04-10	10 percent owner
		2012-10-16	10 percent owner
		2010-06-30	other: Former 10% Owner
		2009-10-05	10 percent owner
		2009-09-03	other: No longer 10% owner
		2007-05-07	10 percent owner
		2009-04-03	10 percent owner

Alta Biopharma Partners Iii Lp Latest Holdings Summary

Alta Biopharma Partners Iii Lp currently owns a total of 2 stocks. Among these stocks, Alta Biopharma Partners Iii Lp owns 2,336,387 shares of Aegerion Pharmaceuticals Inc (AEGR) as of October 16, 2012, with a value of $5 Million and a weighting of 100%. Alta Biopharma Partners Iii Lp also owns 215 shares of Molecular Templates Inc (MTEM) as of October 5, 2009, with a value of $71 and a weighting of 0%.

Latest Holdings of Alta Biopharma Partners Iii Lp

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
AEGR	Aegerion Pharmaceuticals Inc	2012-10-16	2,336,387	1.97	4,602,682
MTEM	Molecular Templates Inc	2009-10-05	215	0.33	71

Holding Weightings of Alta Biopharma Partners Iii Lp

Alta Biopharma Partners Iii Lp Form 4 Trading Tracker

According to the SEC Form 4 filings, Alta Biopharma Partners Iii Lp has made a total of 0 transactions in Aegerion Pharmaceuticals Inc (AEGR) over the past 5 years. The most-recent trade in Aegerion Pharmaceuticals Inc is the sale of 200,733 shares on October 16, 2012, which brought Alta Biopharma Partners Iii Lp around $4 Million.

According to the SEC Form 4 filings, Alta Biopharma Partners Iii Lp has made a total of 0 transactions in Molecular Templates Inc (MTEM) over the past 5 years. The most-recent trade in Molecular Templates Inc is the acquisition of 1,587 shares on October 5, 2009, which cost Alta Biopharma Partners Iii Lp around $500,000.

Insider Trading History of Alta Biopharma Partners Iii Lp

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Alta Biopharma Partners Iii Lp Trading Performance

GuruFocus tracks the stock performance after each of Alta Biopharma Partners Iii Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Alta Biopharma Partners Iii Lp is -6.5%. GuruFocus also compares Alta Biopharma Partners Iii Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Alta Biopharma Partners Iii Lp within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Alta Biopharma Partners Iii Lp's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Alta Biopharma Partners Iii Lp

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	33
Relative Return to S&P 500(%)	30.48

Alta Biopharma Partners Iii Lp Ownership Network

Ownership Network List of Alta Biopharma Partners Iii Lp

No Data

Ownership Network Relation of Alta Biopharma Partners Iii Lp

Alta Biopharma Partners Iii Lp Owned Company Details

What does Cara Therapeutics Inc do?

Who are the key executives at Cara Therapeutics Inc?

Alta Biopharma Partners Iii Lp is the 10 percent owner of Cara Therapeutics Inc. Other key executives at Cara Therapeutics Inc include Chief Medical Officer Joana Goncalves , Sec'y; Chief Compliance & G.C. Scott Terrillion , and VP-Research & Development Menzaghi Frederique Ph.d. .

Cara Therapeutics Inc (CARA) Insider Trades Summary

Over the past 18 months, Alta Biopharma Partners Iii Lp made no insider transaction in Cara Therapeutics Inc (CARA). Other recent insider transactions involving Cara Therapeutics Inc (CARA) include a net sale of 60,412 shares made by Christopher Posner , a net sale of 5,476 shares made by Joana Goncalves , and a net sale of 5,236 shares made by Scott Terrillion .

In summary, during the past 3 months, insiders sold 3,668 shares of Cara Therapeutics Inc (CARA) in total and bought 0 shares, with a net sale of 3,668 shares. During the past 18 months, 74,117 shares of Cara Therapeutics Inc (CARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 74,117 shares.

Cara Therapeutics Inc (CARA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cara Therapeutics Inc Insider Transactions

No Available Data

What does Macrogenics Inc do?

Who are the key executives at Macrogenics Inc?

Alta Biopharma Partners Iii Lp is the 10 percent owner of Macrogenics Inc. Other key executives at Macrogenics Inc include Acting General Counsel Jeffrey Stuart Peters , SVP & CFO and Secretary James Karrels , and Sr VP & BPD & Manufacturing Thomas Spitznagel .

Macrogenics Inc (MGNX) Insider Trades Summary

Over the past 18 months, Alta Biopharma Partners Iii Lp made no insider transaction in Macrogenics Inc (MGNX). Other recent insider transactions involving Macrogenics Inc (MGNX) include a net sale of 163,395 shares made by Jeffrey Stuart Peters , a net sale of 48,846 shares made by Ezio Bonvini , and a net purchase of 350,000 shares made by Biotech Target N V .

In summary, during the past 3 months, insiders sold 0 shares of Macrogenics Inc (MGNX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 293,400 shares of Macrogenics Inc (MGNX) were sold and 365,000 shares were bought by its insiders, resulting in a net purchase of 71,600 shares.

Macrogenics Inc (MGNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Macrogenics Inc Insider Transactions

No Available Data

What does CymaBay Therapeutics Inc do?

Who are the key executives at CymaBay Therapeutics Inc?

Alta Biopharma Partners Iii Lp is the 10 percent owner of CymaBay Therapeutics Inc. Other key executives at CymaBay Therapeutics Inc include Chief Scientific Officer Charles Mcwherter , Vice President & Finance Daniel Menold , and General Counsel Paul T Quinlan .

CymaBay Therapeutics Inc (CBAY) Insider Trades Summary

Over the past 18 months, Alta Biopharma Partners Iii Lp made no insider transaction in CymaBay Therapeutics Inc (CBAY). Other recent insider transactions involving CymaBay Therapeutics Inc (CBAY) include a net sale of 171,559 shares made by Charles Mcwherter , a net sale of 93,000 shares made by Paul T Quinlan , and a net sale of 52,442 shares made by Daniel Menold .

In summary, during the past 3 months, insiders sold 0 shares of CymaBay Therapeutics Inc (CBAY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 481,646 shares of CymaBay Therapeutics Inc (CBAY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 481,646 shares.

CymaBay Therapeutics Inc (CBAY)'s detailed insider trading history can be found in Insider Trading Tracker table.

CymaBay Therapeutics Inc Insider Transactions

No Available Data

What does Chimerix Inc do?

Who are the key executives at Chimerix Inc?

Alta Biopharma Partners Iii Lp is the 10 percent owner of Chimerix Inc. Other key executives at Chimerix Inc include Chief Business Officer Michael T. Andriole , Principal Accounting Officer David Jakeman , and director & Chief Executive Officer Michael A. Sherman .

Chimerix Inc (CMRX) Insider Trades Summary

Over the past 18 months, Alta Biopharma Partners Iii Lp made no insider transaction in Chimerix Inc (CMRX). Other recent insider transactions involving Chimerix Inc (CMRX) include a net purchase of 40,000 shares made by Fred A Middleton , a net sale of 6,270 shares made by David Jakeman , and a net sale of 3,029 shares made by Michael T. Andriole .

In summary, during the past 3 months, insiders sold 0 shares of Chimerix Inc (CMRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,239 shares of Chimerix Inc (CMRX) were sold and 40,000 shares were bought by its insiders, resulting in a net purchase of 28,761 shares.

Chimerix Inc (CMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chimerix Inc Insider Transactions

No Available Data

What does Aegerion Pharmaceuticals Inc do?

Who are the key executives at Aegerion Pharmaceuticals Inc?

Alta Biopharma Partners Iii Lp is the 10 percent owner of Aegerion Pharmaceuticals Inc. Other key executives at Aegerion Pharmaceuticals Inc include director & Chief Executive Officer Mary T Szela , other: See Remarks Gregory D Perry , and General Counsel and Secretary Benjamin Harshbarger .

Aegerion Pharmaceuticals Inc (AEGR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aegerion Pharmaceuticals Inc (AEGR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aegerion Pharmaceuticals Inc (AEGR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aegerion Pharmaceuticals Inc (AEGR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aegerion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sunesis Pharmaceuticals Inc do?

Who are the key executives at Sunesis Pharmaceuticals Inc?

Alta Biopharma Partners Iii Lp is the other: Former 10% Owner of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks William P. Quinn .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Molecular Templates Inc do?

Who are the key executives at Molecular Templates Inc?

Alta Biopharma Partners Iii Lp is the 10 percent owner of Molecular Templates Inc. Other key executives at Molecular Templates Inc include 10 percent owner Biotech Target N V , Chief Medical Officer Maurizio Voi , and CFO & Treasurer Sean Mclennan .

Molecular Templates Inc (MTEM) Insider Trades Summary

Over the past 18 months, Alta Biopharma Partners Iii Lp made no insider transaction in Molecular Templates Inc (MTEM). Other recent insider transactions involving Molecular Templates Inc (MTEM) include a net purchase of 4,505,319 shares made by Biotech Target N V ,

In summary, during the past 3 months, insiders sold 0 shares of Molecular Templates Inc (MTEM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Molecular Templates Inc (MTEM) were sold and 533,688 shares were bought by its insiders, resulting in a net purchase of 533,688 shares.

Molecular Templates Inc (MTEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Molecular Templates Inc Insider Transactions

No Available Data

What does Raptor Pharmaceutical Corp do?

Who are the key executives at Raptor Pharmaceutical Corp?

Alta Biopharma Partners Iii Lp is the other: No longer 10% owner of Raptor Pharmaceutical Corp. Other key executives at Raptor Pharmaceutical Corp include Chief Medical Officer Krishna R Polu , Chief Financial Officer Michael P Smith , and Chief Commercial Officer David Happel .

Raptor Pharmaceutical Corp (RPTP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Raptor Pharmaceutical Corp (RPTP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Raptor Pharmaceutical Corp (RPTP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Raptor Pharmaceutical Corp (RPTP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Raptor Pharmaceutical Corp Insider Transactions

No Available Data

What does NeurogesX Inc do?

Who are the key executives at NeurogesX Inc?

Alta Biopharma Partners Iii Lp is the 10 percent owner of NeurogesX Inc. Other key executives at NeurogesX Inc include President and CEO Ron Martell , Exec. V.P. & COO & CFO Stephen F Ghiglieri , and director & 10 percent owner Robert Nelsen .

NeurogesX Inc (NGSX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NeurogesX Inc (NGSX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NeurogesX Inc (NGSX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NeurogesX Inc (NGSX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeurogesX Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Alta Biopharma Partners Iii Lp is the 10 percent owner of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Alta Biopharma Partners Iii Lp made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 14,272 shares made by Daniel R. Chevallard , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 0 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 14,272 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 85,728 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

Alta Biopharma Partners Iii Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Alta Biopharma Partners Iii Lp. You might contact Alta Biopharma Partners Iii Lp via mailing address: One Embarcadero Center, Suite 3700, San Francisco Ca 94111.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.